

The September 1, 2022, article by Provencio et al entitled “Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non–Small-Cell Lung Cancer (NADIM phase II trial)” (*J Clin Oncol* 10.1200/JCO.21.02660) was published with an error.

The first sentence of the caption for Figure 3 read as: Kaplan-Meier curves for (A) PFS and (B) OS according to ctDNA detection after neoadjuvant treatment and Kaplan-Meier curves for (C) PFS and (D) OS by clinical response assessed on CT scans (landmark approach).

It should have read as: Kaplan-Meier curves for (A) PFS and (B) OS **by clinical response assessed on CT scans** and Kaplan-Meier curves for (C) PFS and (D) OS **according to ctDNA detection after neoadjuvant treatment** (landmark approach).

This has been corrected as of September 28, 2022. The authors apologize for the error.

DOI: <https://doi.org/10.1200/JCO.22.02137>

ASCO® Education

Expand Your Education with ASCO Education’s Entire Course Catalog

Your One-Stop Source for Lifelong Learning

- Unlimited access to 100+ courses
- Earn credits CME/CE, MOC, Nursing and Pharmacy
- Stay current with constantly updated oncology information

Learn more at eLearning.asco.org

